Four years in the making, AbbVie and Calibr provide first look into ‘switchable’ CAR-T program

Lei Lei Wu

News Reporter

In 2018, AbbVie and Calibr — a branch of Scripps Research Institute — announced a partnership for a next-gen CAR-T program, then still in its preclinical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Four years in the making, AbbVie and Calibr provide first look into ‘switchable’ CAR-T program

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Four years in the mak­ing, Ab­b­Vie and Cal­i­br pro­vide first look in­to ‘switch­able’ CAR-T pro­gram

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Four years in the making, AbbVie and Calibr provide first look into ‘switchable’ CAR-T program